| Drug Name |
Mitomycin |
| Drug ID |
BADD_D01478 |
| Description |
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.[A193419] Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies.[A193419]
Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC)[L12867] - as well as adjunctly to _ab externo_ glaucoma surgeries. |
| Indications and Usage |
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01DC03 |
| DrugBank ID |
DB00305
|
| KEGG ID |
D00208
|
| MeSH ID |
D016685
|
| PubChem ID |
5746
|
| TTD Drug ID |
D0Y0GH
|
| NDC Product Code |
0143-9279; 68254-0016; 51552-1509; 72819-152; 58623-0045; 16729-246; 38779-0553; 16729-108; 71052-644; 16729-116; 53183-7010; 16729-247; 68083-483; 68001-391; 67457-519; 73212-036; 49771-002; 62158-0005; 68001-389; 67457-520; 67457-996; 69448-002; 0143-9280; 16729-115; 69448-001; 16729-248; 68001-390; 67457-997; 67457-518; 51927-3642; 65050-0058; 67457-995; 69448-003; 72493-103; 68083-484 |
| Synonyms |
Mitomycin | Mitomycin C | Mitomycin-C | Mitocin-C | Mitocin C | MitocinC | NSC-26980 | NSC 26980 | NSC26980 | Ametycine | Mutamycin |
